SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Powerful hand protects businessman from attacking arrow with umbrella blue collar
Job Trends
Biopharmas pull back on layoffs in Q1
The trend of fewer companies letting employees go, which began in the fourth quarter of last year, has continued. However, more employees were on the chopping block in Q1 2026 than in Q1 2025, due mainly to one company’s cuts.
April 16, 2026
 · 
4 min read
 · 
Angela Gabriel
Drug Development
Whitepaper: CDMOs at a Crossroads
In this whitepaper, BioSpace reviews the major trends impacting the CDMO sector and the evolving relationship between sponsors and providers. We examine the key qualities pharma and biotech should consider in CDMO selection, and how the macroeconomic and macrodevelopment factors affecting the space play a role in this selection.
April 15, 2026
 · 
1 min read
 · 
BioSpace Insights
Working bees on honeycomb
Autoimmune disease
BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
April 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Pruning tree branches. Gloved hands hold a branch and cutting shears, the gardener takes care of the park. Vector illustration.
Business
Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico
After divorcing Denali Therapeutics earlier this month, Takeda is now splitting up with Veritas In Silico, pulling back from a partnership that advanced novel small-molecule drugs targeting mRNA.
April 15, 2026
 · 
2 min read
 · 
Tristan Manalac
speed bumps marked in yellow on a residential road. a road in the fog among very old historic willows. a foggy road on a spring morning.
Obesity
Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data
The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.
April 15, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
J&J targets $100B revenue, Replimune rebuffed again and a “Revolution” in pancreatic cancer
Johnson and Johnson kicked off first-quarter earnings season with a “modest” beat and an ambitious goal; Replimune failed again to gain approval for its advanced melanoma therapy, as analysts tout increased accountability brought by the FDA’s new policy of publicizing complete response letters; and Revolution Medicines’ pancreatic cancer candidate doubled survival in one of cancer’s most intractable foes.
April 15, 2026
 · 
1 min read
 · 
Heather McKenzie
Global business concept. Vector of business people running from one country to the other
Job Trends
Could biotech layoffs push life sciences talent to go global?
Amidst rising layoffs in key biotech hubs, global demand for specialized life sciences talent is driving a more borderless, distributed model of scientific work.
April 15, 2026
 · 
6 min read
 · 
Joanna Hart
Contemporary art collage. Group of employees, business people celebrating successful deal. Giand hands shaking. Profitable cooperation. Concept of business, teamwork, career growth
Mergers & acquisitions
5 biopharma M&A deals where the workforce was the prize
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
April 15, 2026
 · 
7 min read
 · 
Annalee Armstrong
FDA
Deep dive: Checking in with the FDA
BioSpace looks back at 2025 and where the FDA is going in 2026.
April 15, 2026
 · 
2 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS